| Recruiting | A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophag NCT07392892 | Pfizer | Phase 2 / Phase 3 |
| Recruiting | Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastat NCT07315854 | Beijing Friendship Hospital | Phase 2 |
| Recruiting | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Juncti NCT07102901 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Recruiting | Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric NCT06768463 | University Medical Center Ho Chi Minh City (UMC) | N/A |
| Recruiting | First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors NCT06157892 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Withdrawn | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 NCT05703555 | Erasmus Medical Center | Phase 2 |
| Recruiting | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People Wit NCT06251973 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | Study of OB-002 in Patients With Refractory Metastatic Cancer NCT05940844 | Orion Biotechnology Polska Sp. z o.o. | Phase 1 |
| Unknown | 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study NCT05955833 | Amsterdam UMC, location VUmc | Phase 1 |
| Recruiting | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cance NCT06121700 | Fudan University | Phase 2 |
| Recruiting | Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer NCT06008925 | CNBG-Virogin Biotech (Shanghai) Ltd. | Phase 1 / Phase 2 |
| Unknown | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer NCT05859477 | Kidney Cancer Research Bureau | Phase 2 |
| Unknown | Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gast NCT05024812 | The First Affiliated Hospital of Zhengzhou University | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Mainte NCT05230771 | Fujian Medical University | Phase 3 |
| Active Not Recruiting | Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Place NCT05025826 | Nantes University Hospital | N/A |
| Recruiting | Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer NCT05183126 | University of Michigan Rogel Cancer Center | Phase 4 |
| Recruiting | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzu NCT05143970 | Institut Paoli-Calmettes | Phase 1 |
| Recruiting | Liver Embolization Approaches for Tumor Management NCT05714124 | IRCCS San Raffaele | — |
| Unknown | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) NCT04739202 | Hospices Civils de Lyon | Phase 2 |
| Active Not Recruiting | Deciphering the Molecular Traits of Non-canonical Responders to Advance Personalized Therapy in Gastric Cancer NCT06877910 | Regina Elena Cancer Institute | — |
| Completed | Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With In NCT04510064 | Fudan University | Phase 2 |
| Unknown | Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer NCT04358354 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 |
| Unknown | Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer NCT04618809 | Fox Chase Cancer Center | N/A |
| Unknown | Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metast NCT04263870 | Sichuan University | Phase 2 |
| Active Not Recruiting | WaKING: Wnt and checKpoint INhibition in Gastric Cancer NCT04166721 | Royal Marsden NHS Foundation Trust | Phase 1 / Phase 2 |
| Completed | TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer NCT03698825 | MedPacto, Inc. | Phase 1 / Phase 2 |
| Unknown | Resistance to Immunotherapy in Gastric Cancer NCT03614013 | Pontificia Universidad Catolica de Chile | — |
| Completed | GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study NCT03751761 | Asan Medical Center | Phase 1 / Phase 2 |
| Completed | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarci NCT03409848 | AIO-Studien-gGmbH | Phase 2 |
| Completed | Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Heal NCT05765357 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Meta NCT03154983 | Zhou Fuxiang | Phase 2 |
| Completed | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal o NCT02310464 | OBI Pharma, Inc | Phase 1 |
| Unknown | An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Adva NCT02668380 | Peking Union Medical College Hospital | — |
| Unknown | Metronomic Chemotherapy in Advanced Gastric Cancer NCT02855788 | Huashan Hospital | Phase 2 |
| Completed | Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer NCT03121807 | Kaohsiung Medical University Chung-Ho Memorial Hospital | N/A |
| Completed | Genotype Guided Chemotherapy in Gastric Cancer Patients NCT02204306 | Central South University | Phase 2 |
| Unknown | Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Canc NCT02002195 | International Group of Endovascular Oncology | — |
| Unknown | The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel NCT01814150 | Gottfried Maya | — |
| Terminated | Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer NCT02076594 | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Phase 3 |
| Unknown | Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metasta NCT01359397 | The Netherlands Cancer Institute | Phase 2 |
| Completed | A Trial of RAD001/Capecitabine in Refractory Gastric Cancer NCT01099527 | Samsung Medical Center | Phase 1 / Phase 2 |
| Terminated | Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) NCT01528501 | Technical University of Munich | Phase 2 |
| Completed | Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric NCT00632268 | National Taiwan University Hospital | Phase 2 |
| Completed | Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophage NCT00253370 | National Cancer Institute (NCI) | Phase 2 |
| Approved For Marketing | International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer NCT02065765 | Eli Lilly and Company | — |